Pimecrolimus Shortage Update: What Patients Need to Know in 2026

If you've been prescribed pimecrolimus (Elidel) for eczema and are struggling to find it at your pharmacy, you're not alone. Many patients report difficulty filling this prescription — leading to the natural question: Is there a pimecrolimus shortage?

Current Pimecrolimus Shortage Status (2026)

As of 2026, pimecrolimus is not listed as an active drug shortage by the FDA. The FDA maintains a public database of current and resolved drug shortages at accessdata.fda.gov, and pimecrolimus does not appear on that list.

However — and this is important — the absence of an FDA shortage listing does not mean pimecrolimus is easy to find everywhere. It means the drug is being manufactured and distributed to the market; it does not guarantee your local pharmacy has it in stock right now.

Why Is Pimecrolimus Hard to Find If There's No Shortage?

There are several reasons pimecrolimus availability varies significantly across pharmacies, even without an official shortage:

Low baseline stocking: Pimecrolimus is a second-line medication with a relatively small patient population. Many pharmacies stock it only in small quantities or on a per-order basis.

Brand vs. generic fragmentation: Brand-name Elidel and generic pimecrolimus are manufactured by different companies (Bausch Health and generics from Teva and others). A pharmacy may stock one but not the other.

Multiple tube sizes: The 1% cream is available in 30g, 60g, and 100g. A pharmacy may carry the 30g but be out of the 60g or 100g — and your prescription may specify a size.

Distribution lag: Even when national supply is adequate, regional distribution delays can create temporary local gaps that take days or weeks to resolve.

FDA black box warning chilling effect: The 2006 FDA black box warning regarding theoretical cancer risk (subsequently not confirmed by clinical evidence) has contributed to lower prescribing rates and, in turn, reduced stocking at some pharmacies.

Has Pimecrolimus Ever Been in a Formal Shortage?

There is no historic record of pimecrolimus being listed on the FDA's official drug shortage database. Unlike many medications that have experienced supply disruptions due to manufacturing issues, active pharmaceutical ingredient (API) problems, or facility inspections, pimecrolimus has not had a publicized nationwide shortage event.

The challenges patients face are primarily related to local pharmacy stocking patterns, insurance barriers, and cost — not a true supply-side shortage.

What Can Patients Do Right Now?

If you're having trouble filling your pimecrolimus prescription, here are the most effective immediate steps:

Check multiple pharmacies. Don't rely on a single pharmacy. Call at least 3–5 locations, including both chain and independent pharmacies.

Be flexible on brand vs. generic. Both are therapeutically equivalent. If one is out of stock, the other may be available.

Use medfinder.

medfinder calls pharmacies near you on your behalf and texts you results, so you don't have to spend hours on hold.

Ask about ordering. If your preferred pharmacy is out of stock, they can often order it and have it in 1–2 business days.

Talk to your doctor about bridge options. A mild topical corticosteroid can often serve as a bridge treatment while you locate pimecrolimus.

Are There Any Expected Changes to Pimecrolimus Availability in 2026?

No major supply disruptions are currently anticipated for pimecrolimus in 2026. Multiple manufacturers produce the generic, which helps support supply stability. The most significant factor affecting patient access remains cost and insurance coverage — not manufacturing capacity.

For help with cost, see our guide on how to save money on pimecrolimus in 2026.